Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

G-BA

- PMLiVE

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

Impetus Digital

- PMLiVE

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved

The real-world findings support the long-term benefits of continuous treatment

- PMLiVE

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...

Genesis Research Group

- PMLiVE

UCB presentation highlights impacts of epilepsy on daily life

The data underlines the consequences of disrupted sleep for patients and caregivers

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

Turn payer insights into impact with omnichannel engagement in market access

By Betty Charleshouse

Amiculum

- PMLiVE

EpilepsyMeds receives Highly Commended recognition at Excellence in Healthcare Partnership Awards 2026

EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.

Genetic Digital

- PMLiVE

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group

- PMLiVE

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

Genesis Research Group

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

By Sarah Theobald

Amiculum

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links